Two Doses Of Dalbavancin Delivered A Week Apart Comparable To Daily Doses Of Conventional Antibiotics In Treating Patients With Bloodborne Staph Infections, Study Finds

HealthDay (8/14, Thompson) reports a study published in JAMA found that “a new way to battle bloodborne staph infections could help save lives while combating the rise of antibiotic-resistant bacteria.” Study results indicated that “two intravenous doses of the antibiotic dalbavancin delivered seven days apart worked just as well as daily IV doses of conventional antibiotics in quelling Staphylococcus aureus bloodstream infections.” Healio (8/14, I.Feller) adds the study found that the “probability of a better outcome with dalbavancin vs. standard therapy was 47.7%, making it noninferior. Clinical efficacy, however, was experienced by 73 of 100 participants in the dalbavancin group and in 72 of 100 participants in the standard therapy group, which the researchers said met criteria for noninferiority.”